CARSGEN-B (02171) rose nearly 4%, and as of the time of writing, it was up 3.96%, trading at HK$16.27 with a turnover of HK$4.9417 million. Recently, according to a post on the company's official social media account, CARSGEN announced it has entered into a clinical collaboration with Dispatch Bio, a biotechnology firm leveraging its first-in-class Flare platform to develop off-the-shelf treatments for solid tumors. The collaboration plans to initiate a Phase I clinical trial in China by 2026. This trial will evaluate the combination therapy DISP-11 in patients with solid tumors. Reportedly, this combination therapy consists of an investigational treatment developed using Dispatch's pioneering Flare platform, which includes its novel tumor-specific virus DV-10, used in conjunction with CARSGEN's BCMA-targeted autologous CAR-T cell product, CT053 (Zevor-cel injection). CT053 has already received approval from China's National Medical Products Administration (NMPA) for the treatment of multiple myeloma.